Ten-year trends in the pharmacological treatment of insomnia

Sleep

Volumn 22, Issue 3, 1999, Pages 371-375

  Walsh, James K ^a,b,c   Schweitzer, Paula K ^a  

^a ST LUKE S HOSPITAL   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST LUKE S HOSPITAL   (United States)

Author keywords

Benzodiazepines; Hypnotics; Insomnia; Pharmacological treatment; Trazodone

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; DOXEPIN; ESTAZOLAM; FLURAZEPAM; HYPNOTIC AGENT; LORAZEPAM; QUAZEPAM; TEMAZEPAM; TRAZODONE; TRIAZOLAM; ZOLPIDEM;

ARTICLE; CLINICAL PRACTICE; DRUG CHOICE; DRUG SAFETY; DRUG USE; HUMAN; INSOMNIA; PRIORITY JOURNAL;

EID: 0033135191     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/22.3.371     Document Type: Article

References (27)

1. Mellinger GD, Balter, Uhlenhuth EH. Insomnia and its treatment: prevalence and correlates. Arch Gen Psychiatry 1985;42:225-232.
2. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. JAMA. 1989;262:1479-1484.
3. Schramm E, Hohagen F, Kappler C, et al. Mental comorbidity of chronic insomnia in general practice attenders using DSM-III-R. Acta Psychiatr Scand 1995;91:10-17.
4. Gislason T, Almqvist M. Somatic diseases and sleep complaints. An epidemiological study of 3,201 Swedish men. Acta Med Scand 1987;221:475-481.
5. Kales A, Caldwell AB, Soldatos CR, et al. Biobehavioral correlates of insomnia. II. Pattern specificity and consistency with the Minnesota Multiphasic Personality Inventory. Psychosom Med 1983;45:341-356.
6. Vollrath M, Wicki W, Angst J. The Zurich study, VIII, insomnia: association with depression, anxiety, somatic syndromes, and course of insomnia. Eur Arch Psychiatry Clin Neurosci 1989;239:113-124.
7. Walsh JK, Engelhardt CL, Hartmann PG. The direct economic cost of insomnia. In: Hypnotics and anxiolytics: Bailliere's clinical psychiatry. London, England: Baillierre Tindall, 1995.
8. Wysowski DK, Baum C. Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Arch Intern Med. 1991;151:1779-1783.
9. Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170-2177.
10. Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J Clin Psychiatry 1991;52(7, suppl):16-23.
11. American Psychiatric Association. APA task force report on benzodiazepine dependence, toxicity and abuse. Washington,DC: American Psychiatric Association, 1990.
12. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacological Reviews 1992;44(2):151-347.
13. Walsh JK, Engelhardt CL. Trends in the pharmacologic treatment of insomnia. J Clin Psychiatry 1992;53(12, suppl):10-17.
14. Shader RI, Greenblatt DJ, Balter MB. Appropriate use and regulatory control of benzodiazepines. J Clin Pharmacol 1991;31:781-784.
15. National Sleep Foundation. The pharmacological management of insomnia: a white paper of the national sleep foundation. Washington,DC: National Sleep Foundation, 1996.
16. National disease and therapeutic index. Plymouth Meeting, PA: IMS America ltd, 1997.
17. Klink ME, Quan SF, Kaltenborn WT, Lebowitz MD. Risk factors associated with complaints of insomnia in a general adult population. Arch Intern Med 1992;152:1634-1637.
18. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997;154:1417-1423.
19. Ustun TB, Privett M, Lecrubier Y, et al: Form, frequency and burden of sleep problems in general health care: a report from the who collaborative study on psychological problems in general health care. Eur Psychiatry 1996;11(suppl 1):5s-10s.
20. Lasagna L, Shader RI. A white paper on the appropriateness of proposals by the FDA to modify labeling of benzodiazepine sedative-hypnotics. J Clin Pharmacol 1994;34:812-815.
21. Piergies AA, Sweet J, Johnson M, Roth-Schechter B, Allard S. The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Intern J Clin Pharmacol Therapeutics 1996; 34(4):178-183.
22. Allard S, Sainati S, Roth-Schechter B, MacIntyre J. Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women. Drug Metabolism and Disposition 1998;26:617-622.
23. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 1998;13:191-198.
24. Nierenberg AA, Keck PE. Management of monoamine oxidase inhibitor-associated insomnia with trazodone. J Clin Psychopharmacol 1989;9:42-45.
25. Metz A, Shader RI. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. Int Clin Psychopharmacol 1990;5:191-194.
26. Thompson Jr JW, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry. 1990; 51:430-433.
27. Warner MD, Peabody CA, Whiteford HA, et al. Trazodone and priapism. J Clin Psychiatry 1987;48:244-245.